Sign Up
S 4303 United States Senate · 117th Congress

Interchangeable Biologics Clarity Act

Summary
Interchangeable Biologics Clarity Act This bill provides a statutory definition for first interchangeable biosimilar biological product and makes other technical changes with respect to the provisions that establish the corresponding periods of market exclusivity.
Issues: ✓ HealthcareSupports HealthcareClarifies biosimilar interchangeability, enabling lower-cost alternatives and improving patient access to biologic treatments.90% confidence
Bill status in committee 1 of 4 stages cleared
Introduction
May 2022
Committee Review
Floor Vote
President
Introduced May 25, 2022 Last action May 25, 2022
Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
2
Key actions
0
Committee
1
May 25, 2022
Committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709-2710)
upper
May 25, 2022
Introduced
Introduced in Senate
upper
1 primary · 2 co-sponsors

Sponsors

Role
Legislator
Party
State
District
P
Photo of Tim Kaine
Tim Kaine
DDemocratic
VA
n/a
Co
Photo of Margaret Wood Hassan
Margaret Wood Hassan
DDemocratic
NH
n/a
Co
Photo of Susan M. Collins
Susan M. Collins
RRepublican
ME
n/a